Vasopressors & Inotropes
immediate assessment
persistent hypotension, mean arterial pressure (MAP) <65 mmHg, or clinical hypoperfusion (mottling, cool extremities, rising lactate, falling urine output) during ongoing fluid resuscitation = vasopressor now, not another reflex bolus.
- reassess volume status quickly: passive leg raise or a POCUS look at the IVC; do not keep giving fluid on reflex if not fluid responsive.
- start early once hypotension or hypoperfusion persists and fluid responsiveness looks unlikely: vasopressor alongside ongoing fluid, not after a fixed volume finishes.
- start norepinephrine while access is sorted; a peripheral line is fine short term, do not wait for a central line.
- target MAP ≥65 mmHg by default; invasive arterial monitoring as soon as available; individualize lower in older adults or chronic hypertensives (below).
- norepinephrine already needed at moderate dose within the first hour of resuscitation
- lactate rising rather than clearing despite an adequate MAP
- new mottling, altered mentation, or UOP <0.5 mL/kg/hr
define & classify
a vasopressor raises blood pressure mainly by increasing systemic vascular resistance (SVR); an inotrope raises cardiac output mainly by increasing myocardial contractility.
- vasodilation → vasopressor
- low cardiac output → inotrope
- mixed shock → targeted combination
| agent | class | receptor / action | best fit |
|---|---|---|---|
| norepinephrine | mixed | α1 +++, β1 ++ | vasodilatory shock, first line (1) |
| epinephrine | mixed | α1 ++, β1 +++, β2 ++ | anaphylaxis; add-on when norepinephrine + vasopressin aren’t enough |
| vasopressin | vasopressor | V1 (vascular smooth muscle) | fixed-dose, catecholamine-sparing add-on (2)(3) |
| dopamine | mixed | dose-dependent: D1 → β1 → α1 | now mostly bradycardia-associated hypotension only (4) |
| phenylephrine | vasopressor | α1 only, pure | narrow: tachyarrhythmia-limited states, salvage |
| dobutamine | inotrope | β1 +++, β2 + | low cardiac output, inotrope not pressor |
| milrinone | inotrope | PDE-3 inhibitor (↑ cAMP) | low cardiac output, renally cleared |
initial management
- norepinephrine 0.01–0.5 mcg/kg/min IV, titrate to MAP ≥65 mmHg; consider 60–65 mmHg in elderly or chronic hypertensives (SSC 2026, individualized targets in older adults (1)).
- peripheral infusion via a large proximal vein is acceptable for up to 24 hr while central access is obtained; extravasation is uncommon with close monitoring (5). Do not delay the drug for the line.
- add vasopressin, fixed 0.03 units/min, once norepinephrine is around 0.25–0.5 mcg/kg/min; not titratable, it stays fixed and spares catecholamine dose.
- hydrocortisone 50 mg IV q6h (200 mg/day) for septic shock with ongoing vasopressor need despite adequate fluids: ICU / senior-level therapy, not for transient hypotension; current guidance sets no vasopressor dose or duration threshold before starting (6).
- add epinephrine 0.01–0.5 mcg/kg/min if MAP still inadequate on norepinephrine + vasopressin; lactate and glucose rise as a drug effect, not necessarily worsening shock.
- angiotensin II or methylene blue are specialist-directed rescue options for true refractory vasodilatory shock, not a ward-level order.
methylene blue: mechanism & cautions
methylene blue inhibits soluble guanylate cyclase, blocking the nitric oxide-cGMP pathway behind pathologic vasodilation in vasoplegic shock (septic, post-cardiopulmonary bypass, drug-induced) (7). Adjunctive rescue only, for shock refractory to norepinephrine, vasopressin and epinephrine; never routine or first-line; ICU / specialist discussion first. Contraindicated in G6PD deficiency (hemolysis, methemoglobinemia). Caution with serotonergic drugs (SSRIs, SNRIs, MAOIs, linezolid): MAO-A inhibition, serotonin syndrome risk. Caution in pulmonary hypertension: blunts pulmonary as well as systemic nitric oxide-mediated vasodilation.
- dobutamine 2.5–10 mcg/kg/min (up to 20) if there’s myocardial dysfunction despite an adequate MAP, cold extremities, or oliguria with a normal-to-full ventricle on POCUS, not an empty, underfilled one.
- milrinone 0.375–0.75 mcg/kg/min is an alternative inotrope, the loading dose is usually skipped in shock since it worsens hypotension. renally cleared, reduce the dose or avoid in acute kidney injury (AKI) or chronic kidney disease (CKD).
reassess
- recheck MAP, lactate trend, capillary refill, and UOP every 30–60 min while titrating.
- a falling lactate and improving mentation matter more than the number on the monitor alone.
- re-image with POCUS if the dose keeps climbing, don’t just add another agent blind.
advanced management
- norepinephrine-equivalent above 1 mcg/kg/min, or 2 or more vasoactive agents = refractory shock: look for a missed cause (undrained source, adrenal insufficiency, occult cardiogenic component), not just a higher dose.
- phenylephrine (peripheral bolus 50–200 mcg (8) or infusion up to 180 mcg/min): reserve for a tachyarrhythmia limiting norepinephrine / epinephrine, or salvage when norepinephrine + low-dose vasopressin fails
- pure α1: drops cardiac output in preload-dependent patients
- a push around norepinephrine initiation was independently associated with higher ICU mortality in a matched cohort (9): use briefly, reassess, do not repeat
- weaning: once MAP is stable off escalating support, taper the most recently added or highest-risk agent first, one at a time; reassess after each step.
troubleshooting
- escalating norepinephrine with a full IVC and B-lines on POCUS → reassess for an occult cardiogenic component, add dobutamine rather than another vasopressor.
- digital mottling or cyanosis on vasopressin → reduce or stop it, do not push past 0.04 units/min.
- new tachyarrhythmia limiting epinephrine or norepinephrine titration → correct K+ and Mg2+, consider phenylephrine as a bridge.
- persistent hypotension despite 3 agents → reassess adrenal axis, source control, and volume status. this is an escalation trigger, not a fourth drug.
- extravasation or a line concern on a peripheral pressor → stop the infusion, aspirate, escalate access urgently.
escalation / ICU
- norepinephrine-equivalent dose above 1 mcg/kg/min
- need for a second or third vasoactive agent to hold MAP ≥65 mmHg
- lactate not clearing despite an adequate MAP and volume status
- a new arrhythmia limiting further titration
- a suspected cardiogenic component needing inotrope titration beyond ward-level monitoring, see cardiogenic shock
- any patient being considered for invasive hemodynamic monitoring or mechanical circulatory support
pearls & pitfalls
- norepinephrine, not dopamine, is first line even in cardiogenic-predominant shock (SOAP-II subgroup) (4).
- no second vasopressor before reassessing volume and cardiac function on POCUS: an under-filled or failing heart needs fluid or an inotrope, not more vasoconstriction.
- starting a pressor too late is a classic error; so is reflexive large-volume fluid in a non-responder: check responsiveness, not a fixed volume script.
- milrinone vs dobutamine: no clear outcome difference head to head (DOREMI trial) (10); renal function is the practical tiebreaker, milrinone accumulates in kidney impairment.
sources
| source | type |
|---|---|
| 1. Surviving Sepsis Campaign 2026 (SCCM/ESICM) | guideline |
| 2. VASST trial, N Engl J Med 2008 | RCT |
| 3. VANISH trial, JAMA 2016 | RCT |
| 4. SOAP-II trial, N Engl J Med 2010 | RCT |
| 5. Tian et al., safety of peripheral vasopressors, Emerg Med Australas 2020 | review |
| 6. SCCM/ESICM 2024 focused update, corticosteroids in sepsis / ARDS / CAP | guideline |
| 7. Management of vasoplegic shock, BJA Education | review |
| 8. Phenylephrine and epinephrine push-dose vasopressors, ACEP Now | review |
| 9. phenylephrine push before continuous norepinephrine in septic shock, CHEST 2020 | cohort |
| 10. DOREMI trial, N Engl J Med 2021 | RCT |
| Oxford Handbook of Critical Care Medicine, 4th ed | textbook |
dosing above follows international guidance. Verify against the current Kuwait / MOH or hospital protocol where locally sensitive.
Last updated · September 2026